Cargando…

Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach

In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paire...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Stefani N., Funk, Kristen E., Wan, Yunhu, Liao, Zhongping, Davies, Peter, Kuret, Jeff, Yang, Austin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249157/
https://www.ncbi.nlm.nih.gov/pubmed/22033876
http://dx.doi.org/10.1007/s00401-011-0893-0
_version_ 1782220299640504320
author Thomas, Stefani N.
Funk, Kristen E.
Wan, Yunhu
Liao, Zhongping
Davies, Peter
Kuret, Jeff
Yang, Austin J.
author_facet Thomas, Stefani N.
Funk, Kristen E.
Wan, Yunhu
Liao, Zhongping
Davies, Peter
Kuret, Jeff
Yang, Austin J.
author_sort Thomas, Stefani N.
collection PubMed
description In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paired helical filaments were isolated from AD brain and subjected to nanoflow liquid chromatography–tandem mass spectrometry analysis. The resulting spectra identified monomethylation of lysine residues as a new tau modification. The methyl-lysine was distributed among seven residues located in the projection and microtubule binding repeat regions of tau protein, with one site, K254, being a substrate for a competing lysine modification, ubiquitylation. To characterize methyl lysine content in intact tissue, hippocampal sections prepared from post mortem late-stage AD cases were subjected to double-label confocal fluorescence microscopy using anti-tau and anti-methyl lysine antibodies. Anti-methyl lysine immunoreactivity colocalized with 78 ± 13% of neurofibrillary tangles in these specimens. Together these data provide the first evidence that tau in neurofibrillary lesions is post-translationally modified by lysine methylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-011-0893-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3249157
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-32491572012-01-11 Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach Thomas, Stefani N. Funk, Kristen E. Wan, Yunhu Liao, Zhongping Davies, Peter Kuret, Jeff Yang, Austin J. Acta Neuropathol Original Paper In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paired helical filaments were isolated from AD brain and subjected to nanoflow liquid chromatography–tandem mass spectrometry analysis. The resulting spectra identified monomethylation of lysine residues as a new tau modification. The methyl-lysine was distributed among seven residues located in the projection and microtubule binding repeat regions of tau protein, with one site, K254, being a substrate for a competing lysine modification, ubiquitylation. To characterize methyl lysine content in intact tissue, hippocampal sections prepared from post mortem late-stage AD cases were subjected to double-label confocal fluorescence microscopy using anti-tau and anti-methyl lysine antibodies. Anti-methyl lysine immunoreactivity colocalized with 78 ± 13% of neurofibrillary tangles in these specimens. Together these data provide the first evidence that tau in neurofibrillary lesions is post-translationally modified by lysine methylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-011-0893-0) contains supplementary material, which is available to authorized users. Springer-Verlag 2011-10-28 2012 /pmc/articles/PMC3249157/ /pubmed/22033876 http://dx.doi.org/10.1007/s00401-011-0893-0 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Paper
Thomas, Stefani N.
Funk, Kristen E.
Wan, Yunhu
Liao, Zhongping
Davies, Peter
Kuret, Jeff
Yang, Austin J.
Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title_full Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title_fullStr Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title_full_unstemmed Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title_short Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
title_sort dual modification of alzheimer’s disease phf-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249157/
https://www.ncbi.nlm.nih.gov/pubmed/22033876
http://dx.doi.org/10.1007/s00401-011-0893-0
work_keys_str_mv AT thomasstefanin dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT funkkristene dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT wanyunhu dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT liaozhongping dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT daviespeter dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT kuretjeff dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach
AT yangaustinj dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach